Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Sales | 71,914 | 64,538 | 48,973 | 31,388 | 30,037 |
| Cost of Goods | 5,807 | 9,136 | 5,732 | 3,601 | 4,909 |
| Gross Profit | 66,107 | 55,402 | 43,241 | 27,787 | 25,128 |
| Operating Expenses | 39,585 | 35,912 | 29,030 | 28,195 | 26,915 |
| Operating Income | 27,329 | 19,626 | 14,943 | 193 | -878 |
| Interest Expense | 11,802 | 4,860 | 2,077 | 2,924 | 2,297 |
| Other Income | 19,802 | -3,464 | -3,660 | -1,134 | -383 |
| Pre-tax Income | 35,329 | 11,302 | 9,206 | -3,865 | -3,558 |
| Income Tax | -192,115 | 410 | 374 | -1,191 | -13,270 |
| Net Income Continuous | 227,444 | 10,892 | 8,832 | -2,674 | 9,712 |
| Net Income Discontinuous | 0 | 0 | 2,588 | 2,147 | 3 |
| Minority Interests | -2,380 | -1,132 | N/A | N/A | N/A |
| Net Income | $229,824 | $12,024 | $11,420 | $-527 | $9,715 |
| EPS Basic Total Ops | 11.61 | 0.59 | 0.56 | -0.03 | 0.49 |
| EPS Basic Continuous Ops | 11.61 | 0.59 | 0.43 | -0.14 | 0.49 |
| EPS Basic Discontinuous Ops | N/A | 0.00 | 0.13 | 0.11 | 0.00 |
| EPS Diluted Total Ops | 10.83 | 0.56 | 0.55 | -0.03 | 0.49 |
| EPS Diluted Continuous Ops | 10.83 | 0.56 | 0.43 | -0.14 | 0.49 |
| EPS Diluted Discontinuous Ops | N/A | 0.00 | 0.12 | 0.11 | 0.00 |
| EBITDA(a) | $40,230 | $25,977 | $17,606 | $2,920 | $210 |